Fig. 4
From: MAP3K8 is a potential therapeutic target in airway epithelial inflammation
Investigation of MAP3K8 inhibitors. (a) A549 cells pre-treated with Tpl2 inhibitors for one hour and cells were stimulated with IL-1β (1ng/ml) for 24 h. Results are shown for IL-6 production (similar results for IL-8 not shown). (b) A549 cells pre-treated with MAP3K8 inhibitors for one hour and proteins for Western blot collected after IL-1β stimulation for 30 min. P-ERK and P-JNK signalling appear unaffected. (c) A549 cells pre-treated with GSK2222867A for one hour and stimulated with IL-1β (1ng/ml) for 8 h. Results are shown for IL-6 production (similar results for IL8 not shown). The compound GSK2222284A produced no change in cytokine production in the same doses (data not shown). (d) A549 cells pre-treated with GSK2222867A for one hour and proteins for Western blotting collected after IL-1β stimulation for 30 min. P-ERK and P-JNK signalling appear unaffected. The gels show repeat labelling of western blots with different antibodies: sections b) and d) each represent an individual blot, with each antibody stain in a separate box